Form 4: Hepion Pharmaceuticals CEO Buys Shares
Insider Transaction (Form 4)
Gary S. Stetz, Interim CEO and a Director of Hepion Pharmaceuticals, Inc., purchased 4,000,000 shares of common stock on August 3, 2026 for $0.05 per share.
Summary
- Open-market purchase: acquired 2,000,000 Common Stock at $0.05 ($100,000) on August 3, 2026; holds 3,250,000 after (Direct).
- Open-market purchase: acquired 2,000,000 Warrants on August 3, 2026; holds 2,000,000 after (Direct).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $100,000, committing personal capital to the stock.
Insider Transactions
Gary S. Stetz — Director, Officer (Interim CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-03 | Open-market purchase | Common Stock | 2,000,000 | $0 | $100.0K | 3,250,000 |
| 2026-08-03 | Open-market purchase | Warrants | 2,000,000 | — | — | 2,000,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-03 | Open-market purchase (2,000,000 shares) |
| 2026-08-03 | Open-market purchase (2,000,000 shares) |
Keywords
insider transaction, Form 4, HEPA, Hepion Pharmaceuticals, Inc., bullish, Gary S. Stetz
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.